Research Topics
| H TremlettSummaryAffiliation: University of British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Asthma and multiple sclerosis: an inverse association in a case-control general practice populationH L Tremlett
Department of Medicine Neurology, University of Wales College of Medicine, Cardiff, Wales, UK
QJM 95:753-6. 2002..Compared to controls, multiple sclerosis (MS) (Th1-mediated) has been linked to a reduced risk of allergy and asthma (Th2-mediated), based on patient questionnaire studies and a review of asthma medication...
New perspectives in the natural history of multiple sclerosisHelen Tremlett
Faculty of Medicine, Division of Neurology, Multiple Sclerosis Program, University of British Columbia, Vancouver, Canada
Neurology 74:2004-15. 2010....
Impact of multiple sclerosis relapses on progression diminishes with timeH Tremlett
Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
Neurology 73:1616-23. 2009..Current literature is conflicting and focused on early relapses. We investigated the effects of relapses at different stages on disability progression...- Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similaritiesHelen Tremlett
Dept of Medicine Neurology, rm S178, 2211 Wesbrook Mal, University of British Columbia, Vancouver, BC V6T 2B5, Canada
J Neurol 256:374-81. 2009..We aimed to examine how this phenomenon impacts on demographic and clinical comparisons made between PP and SPMS... - Monthly ambient sunlight, infections and relapse rates in multiple sclerosisHelen Tremlett
Faculty of Medicine Neurology, University of British Columbia, Vancouver, B C, Canada
Neuroepidemiology 31:271-9. 2008..Monthly variation in multiple sclerosis (MS) relapses has been found. The relationship between seasonal environmental factors, infections, serum vitamin D [25(OH)D] and MS relapses is undetermined... - Relapses in multiple sclerosis are age- and time-dependentH Tremlett
Department of Medicine Neurology, rm S178, 2211 Wesbrook Mall, University of British Columbia, Vancouver BCV6T2B5, Canada
J Neurol Neurosurg Psychiatry 79:1368-74. 2008..To examine the relative relapse-rate patterns over time in a relapsing multiple sclerosis (MS) cohort and to investigate potential predictors of relapse rates and periods of low-relapse activity... - Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing dosesHelen Tremlett
Faculty of Medicine Neurology, University of British Columbia, Canada
Pharmacoepidemiol Drug Saf 17:565-76. 2008..We examined both levels of non-adherence-stopping IMD and missing doses... - Natural history of secondary-progressive multiple sclerosisHelen Tremlett
Department of Medicine Neurology, rm S159, 2211 Wesbrook Mall, University of British Columbia, Vancouver BC V6T 2B5, Canada
Mult Scler 14:314-24. 2008..To examine prognosis and risk factors for progression to and from secondary-progressive multiple sclerosis (SPMS)... - Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspectiveH L Tremlett
University of British Columbia, Department of Medicine, Division of Neurology, UBC Hospital, Vancouver, BC, Canada
Mult Scler 14:94-105. 2008..In addition, 46 deaths suspected by the reporter as being related to IMD treatment were detailed as well as three possible drug interactions... - Liver test abnormalities in multiple sclerosis: findings from placebo-treated patientsH Tremlett
Faculty of Medicine, Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada
Neurology 67:1291-3. 2006..Abnormal test results were associated with higher body mass index (ALT only), male gender (ALT only), and a relapsing-remitting (vs secondary-progressive) course (ALT and AST only)... - Interrupted therapy: stopping and switching of the beta-interferons prescribed for MSHelen L Tremlett
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada
Neurology 61:551-4. 2003..The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNbeta therapy... - Liver injury associated with the beta-interferons for MS: a comparison between the three productsHelen L Tremlett
Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, University of British Columbia, Vancouver, BC, Canada
Neurology 62:628-31. 2004..005) and were higher than reported in clinical trials. Their relative effect on aminotransferases can be approximated as IFNbeta-1b(subcutaneous [SC]) = IFNbeta-1a(SC) > IFNbeta-1a(IM)... - Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomesHelen L Tremlett
University of British Columbia, Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, UBC Site, S159 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
Mult Scler 10:298-301. 2004..However, one patient reaching grade 3 toxicity went on to develop liver failure (previously reported)... - Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosisHelen Tremlett
Department of Medicine Neurology rm S159, Vancouver Hospital and Health Sciences Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
J Neurol 251:1297-303. 2004..However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly... - The natural history of primary progressive MS in British Columbia, CanadaHelen Tremlett
Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada
Neurology 65:1919-23. 2005..The authors examined patient characteristics, disease progression, and associated risk factors in the PP population of British Columbia, Canada... - Disability progression in multiple sclerosis is slower than previously reportedHelen Tremlett
Department of Medicine Neurology, University of British Columbia, Vancouver, Canada
Neurology 66:172-7. 2006..To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception points--clinical onset and date of birth... - Does the season or month of birth influence disease progression in multiple sclerosis?Helen L Tremlett
Department of Medicine, University of British Columbia, Vancouver, Canada
Neuroepidemiology 26:195-8. 2006..9-47.4) chance of requiring a cane later than those born in other months. There was some evidence to suggest that the gestational period had a small but long-lasting effect on later disease progression in British Columbia, Canada... - Is late-onset multiple sclerosis associated with a worse outcome?Helen Tremlett
Department of Medicine Neurology, rm S159, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC V6T 2B5, Canada
Neurology 67:954-9. 2006..To describe the characteristics of late-onset multiple sclerosis (MS) (LOMS, 50+ years) vs adult-onset MS (AOMS, 16 to <50 years) and examine prognosis and associated risk factors... - High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal studyS Chan
Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada
Mult Scler 17:361-7. 2011..Post-marketing studies and case reports have linked beta-interferon (IFNβ) treatment with liver enzyme abnormalities and liver injuries in patients with multiple sclerosis (MS). Few predictors of risk exist... - Disease onset in familial and sporadic primary progressive multiple sclerosisM Koch
Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada
Mult Scler 16:694-700. 2010..Our findings suggest a hereditary component to the disease process of PPMS. It would be worthwhile to identify patients with familial PPMS for future research on disease modifying genes in MS... - Relative mortality and survival in multiple sclerosis: findings from British Columbia, CanadaE Kingwell
Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
J Neurol Neurosurg Psychiatry 83:61-6. 2012..To examine mortality and factors associated with survival in a population based multiple sclerosis (MS) cohort... - Longitudinal follow-up of "benign" multiple sclerosis at 20 yearsAna Luiza Sayao
Department of Medicine Neurology, University of British Columbia, Vancouver, BC, Canada
Neurology 68:496-500. 2007..To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset... - Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MSE Kingwell
Faculty of Medicine, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, V6T 2B5 Canada
Neurology 74:1822-6. 2010..Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail... - Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohortsElaine Kingwell
Faculty of Medicine Neurology, Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
J Neurol Sci 292:57-62. 2010..001). If early intervention at mild disability levels is warranted in MS, then the extended delays to medical recognition for young adult-onset and PPMS patients must be addressed... - The natural history of primary progressive multiple sclerosisMarcus Koch
Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada
Neurology 73:1996-2002. 2009..Here, we extend previous analyses in an updated PPMS retrospective cohort study of prevalent cases... - Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugsE Lu
Faculty of Medicine, Experimental Medicine Program, University of British Columbia, Vancouver, BC, Canada
Mult Scler 18:460-7. 2012..The incidence of disease-modifying drug (DMD) exposure during pregnancy in multiple sclerosis (MS) is unknown and limited data exists regarding the potential harm of DMD exposure during pregnancy...